TXG 10x Genomics, Inc. Insider Trading

TXG CEO Serge Saxonov sells 30,000 shares for $1.0M via 10b5-1 plan; holds 1.11M post-sale.

Serge Saxonov executed four separate sales totaling 30,000 shares for $1,033,268.62 on 2026-06-22 under a pre-arranged 10b5-1 trading plan adopted 2025-11-29, reducing his holdings by 2.6% to 1,108,380 shares. The company reported negative net income of $-13,470,000.00 in the latest quarter and operated unprofitably over its most recent full fiscal year, though revenue grew 5.2% year-over-year. His same-ticker sales history shows mixed outcomes: a May 2026 sale generated a +42.2% 30-day return, while a July 2023 sale produced a -23.9% 30-day return. As a scheduled 10b5-1 transaction, this sale is divorced from discretionary timing and does not reflect a judgment call by the executive.

Director Mateo Alan bought 40,000 TXG shares at $11.14 (Feb 21), now -76.4% from 52-week high; co. unprofitable

Mateo Alan, a Director of 10x Genomics, purchased 40,000 shares at $11.14 on 2025-02-21 for $445,572.00, expanding his holdings by 184.4% to 61,691 shares. The purchase occurred at a stock price significantly depressed from the 52-week high of $47.16, with the stock currently trading 76.4% below that peak and down 25.0% in the prior 30 days. The company's fundamentals show deterioration: it is unprofitable with negative net income of -$35.8M against quarterly revenue of $151.7M, and annual revenue growth declined -1.3%. Across his broader trading history, Alan's prior 7 open-market sells achieved a 57.14% well-timed rate, suggesting a pattern of disciplined exit timing; this buy represents a substantial accumulation at depressed valuations against that backdrop.